Accelerating the transition from animal-based to alternative dietary proteins – the dietary shift – is key to reducing the footprint of our food system in terms of greenhouse gas emissions (GHG), energy, water and land use, and other relevant environmental impacts, and for improving the health and well-being of people, animals and the planet. GIANT LEAPS delivers the strategic innovations, methodologies, and open-access datasets to speed up this dietary shift, in line with the Farm-to-Fork strategy and contributing to the Green Deal target of reaching climate neutrality by 2050. Achieving the dietary shift in practice is inherently complex due to the diverse set of actors involved and further hindered by major knowledge gaps, scattered across the various alternative protein sources and the domains of health (safety, allergenicity and digestibility), environment (GHGs and other environmental and climate impacts, biodiversity, circularity), and/or barriers to adoption (technological, sensory, and consumer acceptance). The GIANT LEAPS consortium consists of the key actors and spans all expertise to address relevant knowledge gaps and proactively engages to arrive at optimized future diets based on alternative proteins that are broadly accepted across stakeholder groups. In order to deliver required insights for short-, mid- and long-term decision making and impact, GIANT LEAPS protein sources have been selected for either targeted or full assessment based on their current level of specification. The innovations and improved methods combined with accessible and comprehensive information, generated for a wide collection of alternative proteins, will enable policymakers to prioritise changes in the food system towards the dietary shift based on desired impact, value chain actors to make strategic scientific, business and investment choices, and the general public to make more sustainable and healthy dietary choices.

Europe urgently needs to find pathways towards agroecological transition of agroecosystems in support to food security, climate change resilience, biodiversity and soil carbon stocks restoration. In PHENET, the European Research Infrastructures (RI) on plant phenotyping (EMPHASIS), ecosystems experimentation (AnaEE), long-term observation (eLTER) and data management and bioinformatics (ELIXIR) will join their forces to co-develop, with a diversity of innovative companies, new tools and methods - meant to contribute to new RI services - for the identification of future-proofed combinations of species, genotypes and management practices in front of the most likely climatic scenarios across Europe. Ambitioning to go beyond current highly instrumented but often spatially and temporally limited RI installations, PHENET derived services will allow wide access to enlarged sources of in-situ phenotypic and environmental data thanks to (i) new AI-based multi (agroecology-related) traits multi-sensors devices (ii) to unleashed access to high resolution Earth Observation data connected to ground based data, (iii) FAIR data support for connection with (iv) new generation of predictive modeling solutions encompassing AI and digital twins. Developments will be challenged by and implemented in a series of eight Use Cases covering a large range of agroecosystems but also of ecosystems to demonstrate portability of solutions. Several of these Use Cases will mobilize on-farm data. A large effort will be devoted to training RI staff and beyond through a sustained collection of training material fed by experts. Outreaching activities will aim at enlarging the range of RI users. PHENET will not only strengthen RI but will also have major impact on the development of innovative companies on phenotyping, envirotyping and precision agriculture as well as on the emergence of climate smart crop varieties and innovative practices fitted to climate change and agroecological transition.

TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded under FP7. The TRANSVAC2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. TRANSVAC2 will complement and integrate with existing European research infrastructures in both the public and private sectors. TRANSVAC2 will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and -by providing integrated and overarching vaccine R&D services- will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe. The impact of TRANSVAC2 will be maximised by two external advisory bodies. An independent Scientific & Ethics Advisory Committee will provide recommendations surrounding scientific-technical and ethical issues, whereas the coordination of TRANSVAC2 with other related initiatives and the further promotion of the long-term stability of a European vaccine R&D infrastructure will be supported by a Board of Stakeholders comprising representatives of policy and decision makers, industry associations and European infrastructures.